Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Treasury Shares: 2023-2025

Historic Treasury Shares for 4D Molecular Therapeutics (FDMT) over the last 2 years, with Sep 2025 value amounting to $698,019.

  • 4D Molecular Therapeutics' Treasury Shares rose 112.38% to $698,019 in Q3 2025 from the same period last year, while for Sep 2025 it was $698,019, marking a year-over-year increase of 112.38%. This contributed to the annual value of $361,997 for FY2024, which is 99.80% up from last year.
  • 4D Molecular Therapeutics' Treasury Shares amounted to $698,019 in Q3 2025, which was down 3.73% from $725,101 recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Treasury Shares high stood at $748,380 for Q1 2025, and its period low was $181,181 during Q4 2023.
  • Its 3-year average for Treasury Shares is $438,920, with a median of $345,332 in 2024.
  • Data for 4D Molecular Therapeutics' Treasury Shares shows a peak YoY soared of 256.54% (in 2025) over the last 5 years.
  • 4D Molecular Therapeutics' Treasury Shares (Quarterly) stood at $181,181 in 2023, then skyrocketed by 99.80% to $361,997 in 2024, then skyrocketed by 112.38% to $698,019 in 2025.
  • Its Treasury Shares stands at $698,019 for Q3 2025, versus $725,101 for Q2 2025 and $748,380 for Q1 2025.